Met Life Investment Management, LLC Arcutis Biotherapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 61,658 shares of ARQT stock, worth $570,953. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,658
Previous 61,658
-0.0%
Holding current value
$570,953
Previous $573,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$108 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$102 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$99.3 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$81.4 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$79.8 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $557M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...